What smart money is saying about Starling Therapeutics, Inc.
STLN
No fund has written a full thesis on Starling Therapeutics, Inc. in our archive, but 1 fund letter reports a position in it — most recently Cedar Grove Capital Management Multi-Strategy Composite in September 2026.
Get an email when a fund writes about it
1
Reported positions
1
Bought
0
Sold
1
Letter
Position history
Every position in Starling Therapeutics, Inc. on record in the archive was reported in Q3 2026, across 1 fund letter — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 1 | 0 | 0 |
Fund activity · 1 position · 1 move
- September 2026
“During the quarter, we increased our positions in Abivax (ABVX), Evolv Technologies (EVLV), Tantalus System Holding (GRID.TO), Hims and Hers Health (HIMS), Kits Eyecare (KITS.TO), LENSAR (LNSR), Nektar Therapeutics (NKTR), Hydreight Technologies (NURS.V), The RealReal (REAL), and Starling Oncology (STLN), formerly known as The Oncology Institute (TOI).”
Starling Therapeutics, Inc.
Read the letters behind these Starling Therapeutics, Inc. positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger